Table 3.
Summary of trials of PEG-IFN plus RBV in coinfected patients
| Author, year | Genotype: treatment duration (week) | Type of PEG-IFN | RBV dose (mg/day) | n | Virologic response at end of treatment, n (%) | SVR,*n (%) | Withdrawals owing to adverse events, n (%) |
|---|---|---|---|---|---|---|---|
| Perez-Olmeda et al. 2003 [53] | Genotype 1: 48 Genotypes 2, 3: 24 | alfa-2b | 800 | 68 | 27 (40) | 19 (28) | 10 (15) |
| Voigt et al. 2003 [54] | Genotype 1: 48 Genotypes 2, 3: 24 | alfa-2b | 800 | 72 | 33 (46) | 19 (26) | 12 (17) |
| Carrat et al. 2004 [57] | All genotypes: 8 | alfa-2b | 800 | 205 | NA | 55 (27) | 77 (38) |
| Chung et al. 2004 [58] | All genotypes: 48 | alfa-2a | 600† | 66 | 27 (41) | 18 (27) | 8 (12) |
| Torriani et al. 2004 [56] | All genotypes: 48 | alfa-2a | 800 | 289 | NA | 115 (40) | NA (12) |
| Moreno et al. 2004 [55] | All genotypes: 48 | alfa-2b | 800 | 35 | 14 (40) | 11 (31) | 6 (17) |
Reprinted with permission from Rockstroh [52].
NA, not available; PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virologic response.
*
Negative for HCV RNA 24 weeks after end of treatment.
†
Increased to 1000 mg/day at 12 weeks.